Literature DB >> 16033076

Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients.

F Thanner1, M W Sütterlin, M Kapp, L Rieger, A K Morr, P Kristen, J Dietl, A M Gassel, Th Müller.   

Abstract

BACKGROUND: Heat shock protein 27 (hsp27) is a molecular chaperone which supports cells to keep their homeostasis under stressful conditions. It is associated with resistance to chemotherapeutics, radiation and hyperthermia. The aim of this retrospective study was to investigate the prognostic value of hsp27 for patients with node-negative breast cancer.
MATERIALS AND METHODS: Paraffin sections of 191 patients were stained immunohistochemically with a monoclonal antibody against hsp27. Median follow-up was 177 months. The results were correlated with clinical and histopathological parameters using the Chi-square test.
RESULTS: There was no significant correlation between hsp27 expression and standard histopathological features or the proliferation marker ki-67. Disease-free survival (DFS) was not altered for patients expressing hsp27-positive tumors, whereas overall survival (OS) [p=0. 02] and survival after first recurrence (SR) [p=0.01] were significantly decreased.
CONCLUSION: The expression of hsp27 in primary breast cancers is associated with a short survival for node-negative patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033076

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  22 in total

1.  Expression and distribution of HSP27 in response to G418 in different human breast cancer cell lines.

Authors:  Lu Qian; Zhiyi Zhang; Ming Shi; Ming Yu; Meiru Hu; Qing Xia; Beifen Shen; Ning Guo
Journal:  Histochem Cell Biol       Date:  2006-05-30       Impact factor: 4.304

2.  Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing's sarcoma.

Authors:  Cristina Zanini; Francesco Pulerà; Franco Carta; Giuliana Giribaldi; Giorgia Mandili; Milena Maria Maule; Marco Forni; Franco Turrini
Journal:  Virchows Arch       Date:  2007-12-08       Impact factor: 4.064

Review 3.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

4.  Heat shock protein 27 is required for sex steroid receptor trafficking to and functioning at the plasma membrane.

Authors:  Mahnaz Razandi; Ali Pedram; Ellis R Levin
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

5.  [Biology behavior of head and neck squamous cell cancer cells changes after knocking down heat shock protein 27].

Authors:  Zhen-Kun Zhu; Yu-Shang Wang; Xin Xu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

6.  Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma.

Authors:  Xiaofei Chang; Keishi Yamashita; David Sidransky; Myoung Sook Kim
Journal:  Int J Oncol       Date:  2011-01-21       Impact factor: 5.650

Review 7.  The role of heat shock proteins in bladder cancer.

Authors:  Joseph Ischia; Alan I So
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 8.  Heat shock proteins in animal neoplasms and human tumours--a comparison.

Authors:  Mariarita Romanucci; Tania Bastow; Leonardo Della Salda
Journal:  Cell Stress Chaperones       Date:  2008-03-12       Impact factor: 3.667

9.  Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma.

Authors:  Elie Hadchity; Marie-Thérèse Aloy; Christian Paulin; Emma Armandy; Emmanuel Watkin; Robert Rousson; Martin Gleave; Olivier Chapet; Claire Rodriguez-Lafrasse
Journal:  Mol Ther       Date:  2009-05-12       Impact factor: 11.454

10.  Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins.

Authors:  Liang Zhao; Li Liu; Shuang Wang; Yan-fei Zhang; Li Yu; Yan-qing Ding
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.